北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 基础医学院  > 病原生物学系  > 期刊论文
学科主题: 基础医学
题名:
Association of Preexisting Drug-Resistance Mutations and Treatment Failure in Hepatitis B Patients
作者: Ma, Jie1,2; Zhang, Yingchun2; Chen, Xinyue3; Jin, Yi3; Chen, Dexi1; Wu, Yun2; Cui, Jing2; Wang, Haitao2; Liu, Jia5; Li, Ning1,3,4; Gao, Feng6
刊名: PLOS ONE
发表日期: 2013-07-30
DOI: 10.1371/journal.pone.0067606
卷: 8, 期:7
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: REPLICATION IN-VITRO ; LAMIVUDINE THERAPY ; VIRUS POLYMERASE ; NAIVE PATIENTS ; YMDD-MOTIF ; INFECTION ; HBV ; POPULATIONS ; HIV ; RECOMMENDATIONS
英文摘要:

The role of preexisting minority drug-resistance mutations in treatment failure has not been fully understood in chronic hepatitis B patients. To understand mechanisms of drug resistance, we analyzed drug-resistance mutations in 46 treatment-failure patients and in 29 treatment-naive patients and determined linkage patterns of the drug-resistance mutations in individual viral genomes using a highly sensitive parallel allele-specific sequencing (PASS) method. Lamivudine resistance (LAMr) mutations were predominant in treatment-failure patients, irrespective of the inclusion of LAM in the regimen. The primary LAMr mutations M204V and M204I were detected in 100% and 30% of the treatment-failure patients, respectively. Two secondary LAMr mutations (L180M and V173L) were also found in most treatment-failure patients (87% and 78%, respectively). The linkages containing these three mutations dominated the resistant viruses. Importantly, minority LAMr mutations present in < 2% of the viral population were detected in 83% of the treatment-naive patients. Moreover, the low-frequency same linked LAMr mutations (< 0.15%) were detected in 24% of the treatment-naive patients. Our results demonstrate that the selection of preexisting minority linked LAMr mutations may be an important mechanism for the rapid development of LAM resistance, caution the continuous use of LAM to treat drug-experienced and -naive hepatitis B patients, and underline the importance of the detection of minority single and linked drug-resistance mutations before initiating antiviral therapy.

语种: 英语
项目资助者: China Primary Health Care Foundation
WOS记录号: WOS:000323114200004
Citation statistics:
内容类型: 期刊论文
版本: 出版稿
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63221
Appears in Collections:基础医学院_病原生物学系_期刊论文

Files in This Item:
File Name/ File Size Content Type Version Access License
Association of Preexisting Drug-Resistance Mutations and Treatment Failure in Hepatitis B Patients.pdf(755KB)期刊论文出版稿限制开放 联系获取全文

作者单位: 1.Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
2.Beijing Inst Liver Dis, Beijing, Peoples R China
3.Beijing Baihuirui Biotechnol Inc, Beijing, Peoples R China
4.Capital Med Univ, Beijing Youan Hosp, Dept Med, Beijing, Peoples R China
5.Capital Med Univ, Beijing Youan Hosp, Dept Surg, Beijing, Peoples R China
6.Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100871, Peoples R China

Recommended Citation:
Ma, Jie,Zhang, Yingchun,Chen, Xinyue,et al. Association of Preexisting Drug-Resistance Mutations and Treatment Failure in Hepatitis B Patients[J]. PLOS ONE,2013,8(7).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Ma, Jie]'s Articles
[Zhang, Yingchun]'s Articles
[Chen, Xinyue]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Ma, Jie]‘s Articles
[Zhang, Yingchun]‘s Articles
[Chen, Xinyue]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace